Es gab 50 kürzliche Insider-Transaktionen für Ocular Therapeutix, Inc. (OCUL), darunter 19 Käufe und 24 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $44.07M und die gesamten Insider-Verkäufe auf $3.1M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Heier Jeffrey S., Dugel Pravin, Kaiser Peter. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — OCUL
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-02-23 |
Heier Jeffrey S. |
Chief Scientific Officer |
Informierter Verkauf |
3,057 |
$8.28 |
$25.31K |
323,368 |
| 2026-02-23 |
Dugel Pravin |
See Remarks |
Informierter Verkauf |
20,056 |
$8.28 |
$166.06K |
3,013,022 |
| 2026-02-23 |
Kaiser Peter |
Chief Development Officer |
Informierter Verkauf |
2,810 |
$8.28 |
$23.27K |
269,108 |
| 2026-02-23 |
Nayak Sanjay |
Chief Strategy Officer |
Informierter Verkauf |
1,759 |
$8.28 |
$14.56K |
330,653 |
| 2026-02-20 |
Lindstrom Richard L Md |
Director |
Informierter Kauf |
60,229 |
$7.66 |
$461.35K |
246,933 |
| 2026-02-20 |
Waheed Nadia |
Chief Medical Officer |
Informierter Verkauf |
3,510 |
$7.74 |
$27.17K |
314,907 |
| 2026-02-12 |
Dugel Pravin |
See Remarks |
Informierter Verkauf |
124,882 |
$9.04 |
$1.13M |
3,033,078 |
| 2026-02-12 |
Notman Donald |
Chief Operating Officer |
Informierter Verkauf |
11,446 |
$9.04 |
$103.47K |
366,356 |
| 2026-02-12 |
Nayak Sanjay |
Chief Strategy Officer |
Informierter Verkauf |
10,348 |
$9.04 |
$93.55K |
332,412 |
| 2026-02-12 |
Waheed Nadia |
Chief Medical Officer |
Informierter Verkauf |
7,863 |
$9.04 |
$71.08K |
318,417 |
| 2026-02-04 |
Notman Donald |
Chief Operating Officer |
Informierter Verkauf |
6,035 |
$8.54 |
$51.54K |
377,802 |
| 2026-02-02 |
Notman Donald |
Chief Operating Officer |
Informierter Verkauf |
5,455 |
$9.14 |
$49.86K |
383,837 |
| 2026-01-21 |
Robinson David Wayne |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2026-01-21 |
Robinson David Wayne |
Global Cco |
RSU-Zuteilung |
136,000 |
- |
- |
136,000 |
| 2026-01-20 |
Robins Jason Shand |
Interim CFO |
Unbekannt |
110,600 |
$8.12 |
$898.07K |
- |
| 2026-01-20 |
Robins Jason Shand |
Interim CFO |
RSU-Zuteilung |
33,000 |
$11.45 |
$377.85K |
33,000 |
| 2026-01-02 |
Heier Jeffrey S. |
Chief Scientific Officer |
RSU-Zuteilung |
240,932 |
$11.82 |
$2.85M |
240,932 |
| 2026-01-02 |
Notman Donald |
See Remarks |
RSU-Zuteilung |
240,932 |
$11.82 |
$2.85M |
240,932 |
| 2026-01-02 |
Kaiser Peter |
Chief Development Officer |
RSU-Zuteilung |
240,932 |
$11.82 |
$2.85M |
240,932 |
| 2026-01-02 |
Nayak Sanjay |
Chief Strategy Officer |
RSU-Zuteilung |
197,650 |
$11.82 |
$2.34M |
197,650 |
| 2026-01-02 |
Waheed Nadia |
Chief Medical Officer |
RSU-Zuteilung |
240,932 |
$11.82 |
$2.85M |
240,932 |
| 2026-01-02 |
Anderman Todd |
Chief Legal Officer |
RSU-Zuteilung |
64,900 |
- |
- |
152,468 |
| 2026-01-02 |
Saroj Namrata |
Chief Business Officer |
RSU-Zuteilung |
240,932 |
$11.82 |
$2.85M |
240,932 |
| 2026-01-02 |
Meyers Steve Lawrence |
Chief Commercial Officer |
RSU-Zuteilung |
197,650 |
$11.82 |
$2.34M |
197,650 |
| 2025-11-26 |
Dugel Pravin |
See Remarks |
Schenkung (gegeben) |
49,754 |
- |
- |
- |
| 2025-11-24 |
Heier Jeffrey S. |
Chief Scientific Officer |
Informierter Verkauf |
3,469 |
$12.04 |
$41.77K |
245,940 |
| 2025-11-24 |
Dugel Pravin |
See Remarks |
Informierter Verkauf |
19,530 |
$12.04 |
$235.14K |
3,157,960 |
| 2025-11-24 |
Kaiser Peter |
Chief Development Officer |
Informierter Verkauf |
3,007 |
$12.02 |
$36.14K |
191,433 |
| 2025-11-24 |
Nayak Sanjay |
Chief Strategy Officer |
Informierter Verkauf |
1,878 |
$12.04 |
$22.61K |
277,860 |
| 2025-11-05 |
Saroj Namrata |
Chief Business Officer |
Informierter Verkauf |
25,865 |
$10.74 |
$277.79K |
174,135 |
| 2025-10-08 |
Anderman Todd |
Chief Legal Officer |
Informierter Verkauf |
11,132 |
$12.34 |
$137.37K |
87,568 |
| 2025-10-02 |
Heier Jeffrey S. |
Chief Scientific Officer |
Informierter Verkauf |
10,502 |
$11.04 |
$115.94K |
249,409 |
| 2025-10-02 |
Kaiser Peter |
Chief Development Officer |
Informierter Verkauf |
9,653 |
$11.03 |
$106.47K |
194,440 |
| 2025-09-09 |
Dugel Pravin |
See Remarks |
Schenkung (erhalten) |
49,754 |
- |
- |
49,754 |
| 2025-09-02 |
Notman Donald |
See Remarks |
Informierter Verkauf |
1,066 |
$12.43 |
$13.25K |
308,807 |
| 2025-08-25 |
Heier Jeffrey S. |
Chief Scientific Officer |
Informierter Verkauf |
3,063 |
$12.04 |
$36.88K |
259,911 |
| 2025-08-25 |
Dugel Pravin |
See Remarks |
Informierter Verkauf |
21,494 |
$12.04 |
$258.79K |
3,227,244 |
| 2025-08-25 |
Kaiser Peter |
Chief Development Officer |
Informierter Verkauf |
3,011 |
$12.04 |
$36.25K |
204,093 |
| 2025-08-25 |
Nayak Sanjay |
Chief Strategy Officer |
Informierter Verkauf |
1,885 |
$12.04 |
$22.7K |
279,738 |
| 2025-08-12 |
Waheed Nadia |
Chief Medical Officer |
RSU-Zuteilung |
122,923 |
$12.48 |
$1.53M |
122,923 |
| 2025-08-11 |
Dugel Pravin |
See Remarks |
Schenkung (erhalten) |
250,361 |
- |
- |
250,361 |
| 2025-06-12 |
Dugel Pravin |
See Remarks |
Schenkung (gegeben) |
50,029 |
- |
- |
3,248,738 |
| 2025-06-11 |
Raines Merilee |
Director |
RSU-Zuteilung |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Lindstrom Richard L Md |
Director |
RSU-Zuteilung |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Graves Adrienne L |
Director |
RSU-Zuteilung |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Warden Charles M |
Director |
RSU-Zuteilung |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Dugel Pravin |
See Remarks |
RSU-Zuteilung |
2,750,000 |
$7.44 |
$20.46M |
2,750,000 |
| 2025-06-11 |
Williams Leslie J. |
Director |
RSU-Zuteilung |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Hong Seung Suh |
Director |
RSU-Zuteilung |
44,000 |
$8.82 |
$388.08K |
44,000 |
| 2025-06-11 |
Saroj Namrata |
Chief Business Officer |
Unbekannt |
316,000 |
$10.27 |
$3.25M |
- |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
